clinuvel pharmaceuticals ltd ( cuv; xetra dax: ur9; … · presentation to international porphyria...
TRANSCRIPT
![Page 1: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/1.jpg)
PresentationtointernationalporphyriapatientgroupMelbourne,AustraliaandLeatherhead,UK,February8,2016
ClinuvelPharmaceuticalsLtd(ASX:CUV;XETRA‐DAX:UR9;ADR:CLVLY)presentedtoaninternationalporphyriapatientmeeting,heldinRotterdam,theNetherlands,onFebruary6,2016.Thepresentationandspeakingnotesareappendedtothisannouncement.‐End‐AboutClinuvelPharmaceuticalsLimitedClinuvelPharmaceuticalsLtd(ASX:CUV;XETRA‐DAX:UR9;ADR:CLVLY)isaglobalbiopharmaceuticalcompanyfocused on developing drugs for the treatment of a range of severe disorders. With its unique expertise inunderstandingtheinteractionoflightandhumanskin,thecompanyhasidentifiedpatientpopulationswithaclinicalneedforphotoprotectionandforrepigmentation.Theworldwideprevalenceofthesepatientgroupsrangefrom5,000to45million.Clinuvel’sleadcompound,SCENESSE®(afamelanotide16mg),wasapprovedbytheEuropeanCommissionin2014forthepreventionofphototoxicityinadultpatientswitherythropoieticprotoporphyria(EPP).HeadquarteredinMelbourne,Australia,ClinuvelhasoperationsinEurope,Switzerland,theUSandSingapore.Formoreinformationgotohttp://www.clinuvel.com.SCENESSE®isaregisteredtrademarkofClinuvelPharmaceuticalsLtd.InvestorenquiriesInvestorRelations@clinuvel.com
Forward‐LookingStatementsThis release to theAustralianSecuritiesExchangeand topressmaycontain forward‐lookingstatements, includingstatements regardingfutureresults,performanceorachievements.Thesestatementsinvolveknownandunknownrisks,uncertaintiesandotherfactorswhichmaycauseClinuvel’sactualresults,performanceorachievementstobemateriallydifferentfromanyfutureresults,performancesorachievementsexpressedorimpliedbytheforward‐lookingstatements.Thesestatementsreflectourcurrentviewswithrespecttofutureeventsandarebasedonassumptionsandsubjecttorisksanduncertainties.Giventheseuncertainties,youshouldnotplaceunduerelianceontheseforward‐lookingstatements.Someofthefactorsthatcouldaffecttheforward‐lookingstatementscontainedhereininclude:thattheFDAmayrequireadditionalstudiesbeyondthestudiesplannedforproductcandidatesormaynotprovideregulatoryclearances,includingforSCENESSE®;thattheFDAmaynotprovideregulatoryapprovalforanyuseofSCENESSE®orthattheapprovalmaybelimited;thatClinuvelmayneverfileanNDAforSCENESSE®regulatoryapprovalintheUS;thattheCompanymaynotbeabletoaccessadequatecapitaltoadvanceitsvitiligoprograms;thattheCompanymaynotbeabletoretainitscurrentpharmaceuticalandbiotechnologykeypersonnelandknowhowforfurtherdevelopmentofitsproductcandidatesormaynotreachfavourableagreementswithpotentialpricingandreimbursementagenciesinEuropeandtheUS.Level5,160QueenStreet T+61396604900 www.clinuvel.comMelbourne,Victoria3000 F+61396604999Australia
For
per
sona
l use
onl
y
![Page 2: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/2.jpg)
InlinewithEuropeanGuidelines onMedicalAdvertisingandUKAdvertisingStandardsforMedicinalProducts,ClinuvelwillnotdiscusstheprofileoftheproductSCENESSE®(afamelanotide16mg)duringthismeeting.Theproductisapprovedtopreventphototoxicityinadulterythropoieticprotoporphyria(EPP)patients.InformationontheproductcanbefoundonClinuvel’swebsiteatwww.Clinuvel.com.Today’sinvitationisappreciatedandisaheadof thelaunchofSCENESSE®inEurope.ThedistributionofSCENESSE®asafirst‐in‐classproduct.Thereareanumberofchallengesinyearstocome,oneoftheseistheperceptionthattheproductcouldbeusedoff‐label;Clinuvelwilldoitsutmosttoavoidthis.Regulatoryconcernscentrearoundthisaspect.
1
For
per
sona
l use
onl
y
![Page 3: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/3.jpg)
Thepossibleforwardlookingstatementsinthisdiscussionare notaimedatinvitingorsolicitinginterestinthecompany.
2
For
per
sona
l use
onl
y
![Page 4: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/4.jpg)
Today’sdiscussionpointsarerelevant tophysicians,expertsinthetreatmentofthedisease,andEPPpatientsandtheirfamilies.
3
For
per
sona
l use
onl
y
![Page 5: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/5.jpg)
Thefirstdiscussionpoint isaimedatcharacterisationofthedisorder.
4
For
per
sona
l use
onl
y
![Page 6: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/6.jpg)
Thestigmaspatientshavereported toourteamsovertheyearsarefoundinanabundanceofletters,emailsandfromphoneconversations(left).Thelabellingofthediseasebybystanders,‘outsiders’,differsfromthedescriptionpatientsseemtogivethemselves(right).
5
For
per
sona
l use
onl
y
![Page 7: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/7.jpg)
In2005therewere anumberofkeyquestionsindevelopingadrugforEPP,howeverthehypothesisofSCENESSE®wasansweredafterthefirststudyin2006.Theresponsesfrompatientsandphysicianshasbeenstrongerthanexpected.
6
For
per
sona
l use
onl
y
![Page 8: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/8.jpg)
In generalonecannotfullyunderstandthesufferingofapatientuntiloneexperiencestheordeal,symptomsanddiseaseher/himself.Thiswillalwaysbethechasmbetweendrugcompaniesandpatients.Adiscussiononhuman’sdiscriminatorysensesandespeciallyEPP‐patients’abilitytodiscern“visiblelight”isled.
7
For
per
sona
l use
onl
y
![Page 9: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/9.jpg)
OvertheyearseightcharacteristicsofEPPhavebeenidentifiedbyourteamsandexperts,andallofthemmakethediseasecomplextoevaluate.Inaddition,astherearenoappropriatescientifictoolstomeasurethecharacteristicsymptoms,theClinuvelprogramledtooptimumsynthesisofamolecule,formulation,environmentandvariableclinicalprogram.
8
For
per
sona
l use
onl
y
![Page 10: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/10.jpg)
Aspartoftheregulatorydiscussionsandfilings,thisdiagramwas developedandisdiscussedtoday.EPPpatientsareself‐limitingtheirabilitytoexposeduetothecharacteristicsofthedisorder.AnumberofbehaviouralcomponentsmakeEPPdifferentfromotherlightinduceddisorders,rarediseasesororphandiseases.
9
For
per
sona
l use
onl
y
![Page 11: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/11.jpg)
Thenexttopicisthepaediatric development.
10
For
per
sona
l use
onl
y
![Page 12: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/12.jpg)
Theestimatedtime ofdevelopmentisapproximately36months,costingmillionsofEUROsincludingproductdevelopment,clinicaltrials,regulatoryfilings,followupofpatients.Theregulatoryviewswilllargelydeterminefurthertimelines.ThesuccessfulcompletionofthedevelopmentofthepaediatricproductdependsoncontinuedsafetyofSCENESSE®reportedinadultEPPpatients,capturedviatheEuropeanEPPDiseaseRegistry(EEDR).
11
For
per
sona
l use
onl
y
![Page 13: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/13.jpg)
Thethirdtopicisriskmanagement.
12
For
per
sona
l use
onl
y
![Page 14: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/14.jpg)
Themaineightpointsarepartoftheprotocolised treatmentofEPPinEurope,alsoexpectedinotherpartsoftheworld.TheoverallcommitmentforanydeveloperofnoveldrugsistoemphasisePHARMACOVIGILANCE,theabilitytobeextravigilantforitspatientslongterm;Clinuvelundertakesthis.
13
For
per
sona
l use
onl
y
![Page 15: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/15.jpg)
Clinuvel’sinitialroll‐outfocusisonthose countrieswithknownpatientpopulations.Thecompany’sdistributioncentreisLeatherhead,UK.
14
For
per
sona
l use
onl
y
![Page 16: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/16.jpg)
WithintheEUeachcountryisassessingtheproductonanumberofcriteria,including: benefit,costtosociety,numberofpatientsexpected and riskofoff‐labeluse.
15
For
per
sona
l use
onl
y
![Page 17: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/17.jpg)
UnderEuropeanmarketingauthorisation,Clinuvelis establishingandmaintaininganEPP‐specificDiseaseRegistry(EEDR).Theownershipofthemedicaldatawillremainwiththeindividualpatientsandresideineachmedicalcentre,howeverthepseudonymisedmedicaldatarelatedtoEPPwillbemade availabletothe EEDR,andClinuvelwill haveunrestrictedaccesstothesedataforanalyticalpurposestofulfilregulatoryrequirementsoflongtermfollowupofpatients.
16
For
per
sona
l use
onl
y
![Page 18: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/18.jpg)
SettimelineshavebeenestablishedbyEMAforClinuvelto reportdatafromitsEuropeanprogram.Thetimelinesgivenhereprovideasample12monthreportingrequirement.
17
For
per
sona
l use
onl
y
![Page 19: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/19.jpg)
Thedataflowestablished forpharmacovigilanceiscomplex.Ateachpointoftheseprocesses,thereare controlsinplaceandallthesecontrolsformpartofapharmacovigilancemanagementsystem.Each‘station’onthechartrequiresindependentauditingofprocesses,propermanagementandadequateprotectionofmedicaldata.Anumberofadvisorybodies,governanceboards(GovernanceBoard‐ GOB;DataSafetyMonitoringBoard‐ DSMB;MelanocyteSignallingExpertGroup‐ MSEG)andthirdpartyauditorsworkaroundtheclockaspartofpharmacovigilancewithSCENESSE®.Thiscomplexsystemiscompulsoryandaimstoprotectsafetyofpatientslongterm.
18
For
per
sona
l use
onl
y
![Page 20: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/20.jpg)
Asummaryis provided.
19
For
per
sona
l use
onl
y
![Page 21: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/21.jpg)
20
For
per
sona
l use
onl
y
![Page 22: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/22.jpg)
21
For
per
sona
l use
onl
y
![Page 23: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/23.jpg)
Intherenaissanceartistsweretryingtocapturelightinshadowson canvas.ClinuvelhopestoprovidelightforEPPpatientswhohaveledalifeonthefringeandindarkness.
22
For
per
sona
l use
onl
y
![Page 24: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/24.jpg)
Clinuvel hasdevotedmorethanadecadetoonedruginonedisorder,theresponseofpatientsandphysicianshasmadethisjourneyworthwhile.
23
For
per
sona
l use
onl
y
![Page 25: Clinuvel Pharmaceuticals Ltd ( CUV; XETRA DAX: UR9; … · Presentation to international porphyria patient group Melbourne, Australia and Leatherhead, UK, February 8, 2016 Clinuvel](https://reader030.vdocuments.us/reader030/viewer/2022011802/5b4fb3467f8b9a2f6e8ce434/html5/thumbnails/25.jpg)
Thankyou fortheinvitation.
24
For
per
sona
l use
onl
y